GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer

Journal of Controlled Release

Volumn 91, Issue 1-2, 2003, Pages 225-231

  Nemunaitis, John ^a,b,c,d  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^b Mary Crowley Medical Research Center   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d Collins Building ^*  (United States)

Author keywords

GMCSF; Lung cancer; Vaccine

Indexed keywords

GENES; PATIENT MONITORING; TISSUE; TUMORS;

IMMUNE STIMULATING ACTIVITY;

CONTROLLED DRUG DELIVERY;

ADENOVIRUS VECTOR; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; PACLITAXEL; PLASMID VECTOR; RECOMBINANT PROTEIN; RETROVIRUS VECTOR; TUMOR VACCINE; VIRUS VECTOR; ANTINEOPLASTIC AGENT; CANCER VACCINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; BONE PAIN; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; DNA VECTOR; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GENE TRANSFER; GENETIC TRANSFECTION; GRAFT FAILURE; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; INFECTION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MYALGIA; NEUTROPENIA; PANCREAS CANCER; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; SURGICAL TECHNIQUE; T LYMPHOCYTE; VACCINATION; VACCINIA VIRUS VECTOR; VIRAL GENE DELIVERY SYSTEM; CHEMISTRY; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LUNG NEOPLASMS; TRANSDUCTION, GENETIC;

EID: 0141990616     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(03)00210-4     Document Type: Conference Paper

References (46)

1. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl. J. Med. 346:2002;92-98.
2. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Natl. Acad. Sci. USA. 90:1993;3539-3543.
3. Lee C.T., Wu S., Ciernik I.F., Chen H., Nadaf-Rahrov S., Gabrilovich D., Carbone D.P. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum. Gene Ther. 8:1997;187-193.
4. Nagai E., Ogawa T., Kielian T., Ikubo A., Suzuki T. Irradiated tumor cells adenovirally engineered to secrete granulocyte/macrophage-colony- stimulating factor establish antitumor immunity and eliminate pre-existing tumors in syngeneic mice. Cancer Immunol. Immunother. 47:1998;72-80.
5. Colombo M.P., Ferrari G., Stoppacciaro A., Parenza M., Rodolfo M., Mavilio F., Parmiani G. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med. 173:1991;889-897.
6. Chang A.E., Li Q., Bishop D.K., Normolle D.P., Redman B.D., Nickoloff B.J. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. Hum. Gene Ther. 11:2000;839-850.
7. Kusumoto M., Umeda S., Ikubo A., Aoki Y., Tawfik O., Oben R., Williamson S., Jewell W., Suzuki T. Phase I clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene. Cancer Immunol. Immunother. 50:2001;373-381.
8. Mastrangelo M.J., Maguire H.C. Jr., Eisenlohr L.C., Laughlin C.E., Monken C.E., McCue P.A., Kovatich A.J., Lattime E.C. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 6:1998;409-422.
9. Spitler L.E., Grossbard M.L., Ernstoff M.S., Silver G., Jacobs M., Hayes F.A., Soong S.J. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony stimulating factor. J. Clin. Oncol. 18:(8):2000;1614-1621.
10. Parmiani G., Rivoltini L., Andreola G., Carrabba M. Cytokines in cancer therapy. Immunol. Lett. 74:2000;41-44.
11. Simons J.W., Jaffee E.M., Weber C.E., Levitsky H.I., Nelson W.G., Carducci M.A., Lazenby A.J., Cohen L.K., Finn C.C., Clift S.M., Hauda K.M., Beck L.A., Leiferman K.M., Owens A.H. Jr., Piantadosi S., Dranoff G., Mulligan R.C., Pardoll D.M., Marshall F.F. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57:1997;1537-1546.
12. Soiffer R., Lynch T., Mihm M., Jung K., Rhuda C., Schmollinger J.C., Hodi F.S., Liebster L., Lam P., Mentzer S., Singer S., Tanabe K.K., Cosimi A.B., Duda R., Sober A., Bhan A., Daley J., Neuberg D., Parry G., Rokovich J., Richards L., Drayer J., Berns A., Clift S., Cohen L.K., Mulligan R.C., Dranoff G. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Natl. Acad. Sci. USA. 95:1998;13141-13146.
13. Jaffee E.M., Hruban R.H., Biedrzycki B., Laheru D., Schepers K., Sauter P.R., Goemann M., Coleman J., Grochow L., Donehower R.C., Lillemoe K.D., O'Reilly S., Abrams R.A., Pardoll D.M., Cameron J.L., Yeo C.J. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19:2001;145-156.
14. Simons J.W., Mikhak B., Chang J.F., DeMarzo A.M., Carducci M.A., Lim M., Weber C.E., Baccala A.A., Goemann M.A., Clift S.M., Ando D.G., Levitsky H.I., Cohen L.K., Sanda M.G., Mulligan R.C., Partin A.W., Carter H.B., Piantadosi S., Marshall F.F., Nelson W.G. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59:1999;5160-5168.
15. Salgia R., Lynch T., Skarin A., Lucca J., Lynch C., Jung K., Hodi F.S., Jaklitsch M., Mentzer S., Swanson S., Lukanich J., Bueno R., Wain J., Mathisen D., Wright C., Fidias P., Donahue D., Clift S., Hardy S., Neuberg D., Mulligan R., Webb I., Sugarbaker D., Mihm M., Dranoff G. A phase I study of vaccination with lethally irradiated, autologous nonsmall cell lung carcinoma cells engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor. Lung Cancer. 29:(Suppl. 1):2000;186.
16. Nemunaitis J., Rabinowe S.N., Singer J.W., Bierman P.J., Vose J.M., Freedman A.S., Onetto N., Gillis S., Oette D., Gold M., Buckner C.D., Hansen J.A., Appelbaum F.R., Armitage J.O., Nadler L.M. Recombinant granulocyte macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New Engl. J. Med. 324:1991;1773-1778.
17. Brandt S.J., Peters W.P., Atwater S.K., Kurtzberg J., Borowitz M.J., Jones R.B., Shpall E.J., Bast R.C. Jr., Gilbert C.J., Oette D.H. Effect of recombinant human granulocyte macrophage colony stimulating factor on hematopoietic reconstitution after high dose chemotherapy and autologous bone marrow transplantation. New Engl. J. Med. 318:1988;869-876.
18. Nemunaitis J., Singer J.W., Buckner C.D., Durnam D., Epstein C., Hill R., Storb R., Thomas E.D., Appelbaum F.R. Use of recombinant granulocyte macrophage macrophage colony stimulating factor in graft failure after bone marrow transplantation. Blood. 76:1990;245-253.
19. Vose J.M., Bierman P.J., Kessinger A., Coccia P.F., Anderson J., Oldham F.B., Epstein C., Armitage J.O. The use of recombinant human granulocyte macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant. 7:1991;139-143.
20. Nemunaitis J., Anasetti C., Storb R., Bianco J.A., Buckner C.D., Onetto N., Martin P., Sanders J., Sullivan K., Mori M., Shannon-Dorsy K., Bowden R., Appelbaum F.R., Hansen J., Singer J.W. Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood. 79:1992;2572-2577.
21. Rowe J.M., Andersen J.W., Mazza J.J., Bennett J.M., Paietta E., Hayes F.A., Oette D., Cassileth P.A., Stadtmauer E.A., Wiernik P.H. A randomized placebo controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 86:1995;457-462.
22. Marrogi A.J., Munshi A., Merogi A.J., Ohadike Y., El-Habashi A., Marrogi O.L., Freeman S.M. Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int. J. Cancer. 74:1997;492-501.
23. Grabstein K.H., Urdal D.L., Tushinski R.J., Mochizuki D.Y., Price V.L., Cantrell M.A., Gillis S., Conlon P.J. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor. Science. 232:1986;506-508.
24. Wing E.J., Magee D.M., Whiteside T.L., Kaplan S.S., Shadduck R.K. Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. Blood. 73:1989;643-646.
25. Beyer J., Schwella N., Zingsem J., Strohscheer I., Schwaner I., Oettle H., Serke S., Huhn D., Stieger W. Hematopoietic rescue after high dose chemotherapy using autologous peripheral blood progenitor cells or bone marrow: a randomized comparison. J. Clin. Oncol. 13:(6):1995;1328-1335.
26. Stone R.M., Berg D.T., George S.L., Dodge R.K., Paciucci P.A., Schulman P., Lee E.J., Moore J.O., Powell B.L., Schiffer C.A. Granulocyte macrophage colony stimulating factor after initial chemotherapy for patients at least 60 years old with primary acute myeloid leukemia. New Engl. J. Med. 332:1995;1671-1677.
27. Dong Z., Yoneda J., Kumar R., Fidler I.J. Angiostatin-mediated suppression of cancer metastases by primary neoplasms engineered to produce granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 188:1998;755-763.
28. Teng M.N., Park B.H., Koeppen H.K., Tracey K.J., Fendly B.M., Schreiber H. Long term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc. Natl. Acad. Sci. USA. 88:1991;3535-3539.
29. Aoki T., Tashiro K., Miyatake S., Kinashi T., Nakano T., Oda Y., Kikuchi H., Honjo T. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc. Natl. Acad. Sci. USA. 89:1992;3850-3854.
30. Porgador A., Feldman M., Eisenbach L. Immunotherapy of tumor metastasis via gene therapy. Nat. Immunol. 13:1994;113-130.
31. Golumbek P.T., Lazenby A.J., Levitsky H.I., Jaffee L.M., Karasuyama H., Baker M., Pardoll D.M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 254:1991;713-716.
32. Gansbacher B., Zier K., Daniels B., Cronin K., Bannerji R., Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172:1990;1217-1224.
33. Fearon E.R., Pardoll D.M., Itaya T., Golumbek P., Levitsky H.I., Simons J.W., Karasuyama H., Vogelstein B., Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 60:1990;397-403.
34. Gansbacher B., Bannerji R., Daniels B., Zier K., Cronin K., Gilboa E. Retroviral vector-mediated gamma interferon gene transfer into tumor cells generates potent and long lasting antitumorimmunity. Cancer Res. 50:1990;7820-7825.
35. Lim M., Simons J.W. Emerging concepts in GM-CSF gene-transduced tumor vaccines for human prostate cancer. Curr. Opin. Mol. Ther. 1:(1):1999;64-71.
36. Jaffee E.M., Dranoff G., Cohen L.K., Hauda K.M., Clift S., Marshall F.F., Mulligan R.C., Pardoll D.M. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res. 53:(10):1993;2221-2226.
37. Carducci M.A., Ayyagari S.A., Sanda M.G., Simons J.W. Gene therapy for human prostate cancer. Translational research in the hormone refractory Dunning prostate cancer model. Cancer. 75:1995;2013-2020.
38. Rosenberg S.A., Blaese R.M., Brenner M.K., Deisseroth A.B., Ledley F.D., Lotze M.T., Wilson J.M., Nabel G.J., Cornetta K., Economou J.S., Freeman S.M., Riddell S.R., Brenner M., Oldfield E., Gansbacher B., Dunbar C., Walker R.E., Schuening F.G., Roth J.A., Crystal R.G., Welsh M.J., Culver K., Heslop H.E., Simons J., Wilmott R.W., Boucher R.C., Siegler H.F., Barranger J.A., Karlsson S., Kohn D., Galpin J.E., Raffel C., Hesdorffer C., Ilan J., Cassileth P., O'Shaughnessy J., Kun L.E., Das T.K., Wong-Staal F., Sobol R.E., Haubrich R., Sznol M., Rubin J., Sorcher E.J., Rosenblatt J., Walker R., Brigham K., Vogelzang N., Hersh E., Eck S.L. Human gene marker/therapy clinical protocols. Hum. Gene Ther. 11:(6):2000;919-979.
39. Cella M., Sallusto F., Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9:(1):1997;10-16.
40. Cella M., Engering A., Pinet V., Pieters J., Lanzavecchia A. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells [see comments]. Nature. 388:(6644):1997;782-787.
41. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:(6673):1998;245-252.
42. Sallusto S.F., Cella M., Danieli C., Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products [see comments]. J. Exp. Med. 182:(2):1995;389-400.
43. Nemunaitis J., Sterman D., Jablons D., Smith J., Fox B., Woo E.Y., Maples P., Lin A., Borellini F., Hege K. A phase I/II study of autologous GM-CSF gene-modified cancer vaccines in subjects with non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;255a.
44. Nemunaitis J., Cunningham C., Senzer N., Maples P., Sterman D., Jablons D., Smith J., Hamilton S., Borellini F., Lin A., Morali S., Hege K. GMCSF modified tumor vaccine clinical update: non small cell lung cancer (NSCLS). Cancer Gene Ther. 10:(Suppl. 1):2003;S36.
45. Hersey P., Coates A.S., McCarthy W.H., Thompson J.F., Sillar R.W., McLeod R., Gill P.G., Coventry B.J., McMullen A., Dillon H., Simes R.J. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J. Clin. Oncol. 20:(20):2002;4181-4190.
46. Nemunaitis J., Jolly D.J. Long-term follow-up of retroviral vector administered gamma-Interferon (γ-IFN) gene in metastatic melanoma. Cancer Gene Ther. 7:(10):2000;1297-1298. Letter to the Editor.